Practices


Xarelto’s risks outweigh the benefits: Beasley Allen principal David Byrne explains

July 16, 2015 - Xarelto is in a new class of blood thinners designed to be an alternative to warfarin for the treatment of blood clots; however, unlike warfarin, there is no antidote to reverse the blood... Read More


$2.4 billion settlement agreement reached in Actos bladder cancer litigation

April 29, 2015 - Takeda Pharmaceutical Co. has agreed to a $2.4 billion settlement to resolve bladder cancer claims tied to its Type 2 diabetes drug Actos. The settlement will compensate an anticipated... Read More


Blood thinner Xarelto dangers discussed by Beasley Allen attorney David Byrne

February 24, 2015 - Today on the Beasley Allen Report, host Gibson Vance interviews fellow Beasley Allen attorney David Byrne on the dangers of the prescription drug Xarelto. Read More


Beasley Allen lawyer Andy Birchfield appointed to leadership role in Xarelto blood thinner multidistrict litigation

February 10, 2015 - Beasley Allen Mass Torts section head Andy Birchfield has been appointed as Co-Lead Counsel for the Plaintiffs Steering Committee (PSC) in multidistrict litigation (MDL) over blood-thinner... Read More


Xarelto blood thinner lawsuits consolidated in Louisiana federal court; drug linked to serious bleeding risk

December 15, 2014 - Nearly two dozen lawsuits filed against Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Corp. over the blood thinner Xarelto have been consolidated in Louisiana federal... Read More


Talcum powder link to ovarian cancer explained

December 11, 2014 - Ted is leading the charge in litigation related to women who have developed ovarian cancer after using talc-containing products like Johnson & Johnson Baby Powder and Shower to Shower body... Read More


Januvia and Byetta may increase chances of developing pancreatic cancer

November 4, 2014 - David Dearing discusses the dangers of type 2 diabetes drugs, such as Januvia and Byetta which have been linked to pancreatic cancer Read More


Actos verdict illustrates companies that co-promote drugs can be held liable for injuries, failure to warn

September 4, 2014 - A federal judge’s decision not to overturn a jury’s $9 billion verdict against Takeda Pharmaceutical Co. and Eli Lilly for withholding bladder cancer risks from doctors and patients... Read More



Testosterone replacement therapy lawsuits expected to climb into the thousands

June 26, 2014 - The lawsuits allege testosterone treatment makers withheld serious risks associated with the product while heavily marketing the therapy to consumers in an effort to drive profits. Read More


back to top